Your browser doesn't support javascript.
loading
Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven australian hospitals.
Steinberg, Julia; Chan, Priscilla; Hogden, Emily; Tiernan, Gabriella; Morrow, April; Kang, Yoon-Jung; He, Emily; Venchiarutti, Rebecca; Titterton, Leanna; Sankey, Lucien; Pearn, Amy; Nichols, Cassandra; McKay, Skye; Hayward, Anne; Egoroff, Natasha; Engel, Alexander; Gibbs, Peter; Goodwin, Annabel; Harris, Marion; Kench, James G; Pachter, Nicholas; Parkinson, Bonny; Pockney, Peter; Ragunathan, Abiramy; Smyth, Courtney; Solomon, Michael; Steffens, Daniel; Toh, James Wei Tatt; Wallace, Marina; Canfell, Karen; Gill, Anthony; Macrae, Finlay; Tucker, Kathy; Taylor, Natalie.
Afiliação
  • Steinberg J; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling St, NSW, 2011, Woolloomooloo, Australia. julia.steinberg@nswcc.org.au.
  • Chan P; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling St, NSW, 2011, Woolloomooloo, Australia.
  • Hogden E; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling St, NSW, 2011, Woolloomooloo, Australia.
  • Tiernan G; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling St, NSW, 2011, Woolloomooloo, Australia.
  • Morrow A; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling St, NSW, 2011, Woolloomooloo, Australia.
  • Kang YJ; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling St, NSW, 2011, Woolloomooloo, Australia.
  • He E; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling St, NSW, 2011, Woolloomooloo, Australia.
  • Venchiarutti R; Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
  • Titterton L; NSW Health, Western Sydney Local Health District, Westmead, NSW, Australia.
  • Sankey L; Monash Health, Melbourne, Victoria, Australia.
  • Pearn A; Cancer Council NSW, Sydney, NSW, Australia.
  • Nichols C; Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, Western Australia, Australia.
  • McKay S; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling St, NSW, 2011, Woolloomooloo, Australia.
  • Hayward A; The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Egoroff N; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
  • Engel A; The University of Sydney, Northern Clinical School Royal North Shore Hospital, Sydney, NSW, Australia.
  • Gibbs P; Personalised Oncology Division, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.
  • Goodwin A; Cancer Genetics Department, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
  • Harris M; Monash Health, Melbourne, Victoria, Australia.
  • Kench JG; Department of Tissue Pathology & Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
  • Pachter N; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Parkinson B; Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, Western Australia, Australia.
  • Pockney P; School of Medicine and Pharmacology, University of Western Australia, Perth, Western, Australia.
  • Ragunathan A; Centre for the Health Economy, Macquarie University, Sydney, NSW, Australia.
  • Smyth C; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
  • Solomon M; Westmead Familial Cancer Services, The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australia.
  • Steffens D; Monash Health, Melbourne, Victoria, Australia.
  • Toh JWT; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Wallace M; Department of Colorectal Surgery, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
  • Canfell K; Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
  • Gill A; Department of Colorectal Surgery, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
  • Macrae F; Department of Colorectal Surgery, The University of Sydney, Westmead Hospital, Westmead, NSW, Australia.
  • Tucker K; Fiona Stanley Hospital, South Metropolitan Health Service, Murdoch, Western Australia, Australia.
  • Taylor N; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, 153 Dowling St, NSW, 2011, Woolloomooloo, Australia.
Hered Cancer Clin Pract ; 20(1): 18, 2022 May 04.
Article em En | MEDLINE | ID: mdl-35509103
ABSTRACT

BACKGROUND:

To inform effective genomic medicine strategies, it is important to examine current approaches and gaps in well-established applications. Lynch syndrome (LS) causes 3-5% of colorectal cancers (CRCs). While guidelines commonly recommend LS tumour testing of all CRC patients, implementation in health systems is known to be highly variable. To provide insights on the heterogeneity in practice and current bottlenecks in a high-income country with universal healthcare, we characterise the approaches and gaps in LS testing and referral in seven Australian hospitals across three states.

METHODS:

We obtained surgery, pathology, and genetics services data for 1,624 patients who underwent CRC resections from 01/01/2017 to 31/12/2018 in the included hospitals.

RESULTS:

Tumour testing approaches differed between hospitals, with 0-19% of patients missing mismatch repair deficiency test results (total 211/1,624 patients). Tumour tests to exclude somatic MLH1 loss were incomplete at five hospitals (42/187 patients). Of 74 patients with tumour tests completed appropriately and indicating high risk of LS, 36 (49%) were missing a record of referral to genetics services for diagnostic testing, with higher missingness for older patients (0% of patients aged ≤ 40 years, 76% of patients aged > 70 years). Of 38 patients with high-risk tumour test results and genetics services referral, diagnostic testing was carried out for 25 (89%) and identified a LS pathogenic/likely pathogenic variant for 11 patients (44% of 25; 0.7% of 1,624 patients).

CONCLUSIONS:

Given the LS testing and referral gaps, further work is needed to identify strategies for successful integration of LS testing into clinical care, and provide a model for hereditary cancers and broader genomic medicine. Standardised reporting may help clinicians interpret tumour test results and initiate further actions.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article